Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + GemOX + Lenvatinib for Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
NCT07263360Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in intrahepatic cholangiocarcinoma (ICC) and gallbladder cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: R0 Resection Rate at 12 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on NCT07263360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263360.